Vascular Augmentation of Late-life Unremitted Depression (VALUeD)
Status:
Unknown status
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
Depression has a high occurrence and causes other problems in older people, two thirds of
these patients will not have a lessening in their condition from routine treatment
medication. About half have a form of depression known as 'vascular depression'.
Augmentation, the addition to, antidepressant treatment with a vascular type of treatment
(such as a group of medications called Calcium Channel Blocker including the medication
called amlodipine) may be effective in this group of patients but previously published
studies have been from highly selected specific patient groups. The investigators would like
to find out if giving amlodipine medication to people with late life non-responding vascular
depression would be acceptable to this patient group. The investigators would also like to
know how they feel while having the treatment and whether this provides a measurable benefit
for those patients and whether those benefits are relevant to the patients. The investigators
would also like to find out the information the investigators need to plan and prepare for a
larger version of this study.
Phase:
Phase 3
Details
Lead Sponsor:
Gateshead Health NHS Foundation Trust
Collaborators:
National Institute for Health Research, United Kingdom Newcastle-upon-Tyne Hospitals NHS Trust